Jeff Martin
Stock Analyst at Roth Capital
(4.42)
# 300
Out of 4,945 analysts
61
Total ratings
60.94%
Success rate
15.79%
Average return
Main Sectors:
Stocks Rated by Jeff Martin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NSP Insperity | Maintains: Buy | $85 → $74 | $52.18 | +41.82% | 9 | Aug 4, 2025 | |
| FC Franklin Covey Co. | Maintains: Buy | $30 → $27 | $19.65 | +37.40% | 8 | Jul 7, 2025 | |
| TACT TransAct Technologies | Maintains: Buy | $6 → $5 | $4.22 | +18.60% | 1 | May 14, 2025 | |
| PERI Perion Network | Upgrades: Buy | $9 → $14 | $8.84 | +58.37% | 8 | May 14, 2025 | |
| OSIS OSI Systems | Maintains: Buy | $224 → $245 | $232.81 | +5.24% | 16 | May 2, 2025 | |
| BGSF BGSF, Inc. | Maintains: Buy | $12 → $9 | $5.79 | +55.57% | 1 | Mar 20, 2025 | |
| BBSI Barrett Business Services | Maintains: Buy | $43 → $45 | $47.03 | -4.32% | 5 | Nov 7, 2024 | |
| HCKT The Hackett Group | Maintains: Buy | $29 → $30 | $20.74 | +44.65% | 6 | Nov 5, 2024 | |
| BWMN Bowman Consulting Group | Maintains: Buy | $47 → $43 | $39.58 | +8.65% | 5 | Aug 8, 2024 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | $5,760 | $1.41 | +408,236.88% | 2 | Nov 15, 2017 |
Insperity
Aug 4, 2025
Maintains: Buy
Price Target: $85 → $74
Current: $52.18
Upside: +41.82%
Franklin Covey Co.
Jul 7, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $19.65
Upside: +37.40%
TransAct Technologies
May 14, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $4.22
Upside: +18.60%
Perion Network
May 14, 2025
Upgrades: Buy
Price Target: $9 → $14
Current: $8.84
Upside: +58.37%
OSI Systems
May 2, 2025
Maintains: Buy
Price Target: $224 → $245
Current: $232.81
Upside: +5.24%
BGSF, Inc.
Mar 20, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $5.79
Upside: +55.57%
Barrett Business Services
Nov 7, 2024
Maintains: Buy
Price Target: $43 → $45
Current: $47.03
Upside: -4.32%
The Hackett Group
Nov 5, 2024
Maintains: Buy
Price Target: $29 → $30
Current: $20.74
Upside: +44.65%
Bowman Consulting Group
Aug 8, 2024
Maintains: Buy
Price Target: $47 → $43
Current: $39.58
Upside: +8.65%
Galmed Pharmaceuticals
Nov 15, 2017
Initiates: Buy
Price Target: $5,760
Current: $1.41
Upside: +408,236.88%